OasisLMS

This activity was supported by unrestricted grants from Ferring, AstraZeneca, Pfizer, Blue
Earth, Lantheus and Calyxo.

After the LUGPA 2025 CME Enduring Program, learners will be able to:

- Evaluate emerging therapies and current standards of care for NMIBC and MIBC.
- Compare procedural innovations in stone management, including aspiration-directed lithotripsy and mini-PCNL.
- Apply updated guidelines and best practices for testosterone therapy in 2025.
- Interpret PSMA PET imaging and utilize advanced PSA biomarkers and genetic testing in prostate cancer care.
- Assess novel surgical approaches, including SP and multiport robotic prostatectomy techniques.
- Identify infrastructure and readiness requirements for implementing radioligand therapy.
- Incorporate advancements in immunotherapy and imaging into clinical decision-making for urologic cancers.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUPGA.

PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians. PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The enduring approval period is: December 18, 2025 – December 18, 2028

Course completion data is submitted to PeerPoint on the first of each month. Once your information has been added, and you are officially eligible to claim CME credit, you will receive an email from aperillo@lugpa.org with instructions on how to do so. 

Disclaimer:
Participants who previously attended the Live LUGPA 2025 CME Program and claimed CME are not eligible to claim CME credit for the corresponding enduring activity.